Promising Phase III data for a new passive vaccine against RSV
May 10, 2021Infection by Respiratory Syncytial Virus (RSV) is the leading cause of hospitalization in infants. The currently available preventive treatment is a monthly injection with an anti-RSV antibody, which is only given to high-risk infants and only temporarily provides protection due to a limited half-life. Now, a new antibody against RSV, which was developed by scientists of Amsterdam UMC
spin-off AIMM Therapeutics, has come one step closer to market authorization, showing positive results in a Phase III clinical trial performed by pharma companies Astra Zeneca and Sanofi. This antibody, being more stable than the existing antibody, will only need to be administered once per RSV-season and should become available to all infants.
For more information click here.
Photo credit: Respiratory syncytial virus (RSV) infection – Case 288 by Yale Rosen. Photo is cropped.
More news
PULSE Sport Wins Prestigious Dutch Sports Innovation Award 2024
PULSE Sport, a start-up from the Demonstrator Lab, has reached a significant milestone by winning the prestigious 14th Dutch Sports Innovation Award. The company’s flagship product, a cutting-edge athlete management system, integrates advanced software and artificial intelligence to revolutionize athlete health and performance monitoring. About the Innovation PULSE Sport’s athlete management system provides a holistic […]
News
Biotech boost(er) for life sciences innovations
Amsterdam researchers have secured Biotech Booster funding for a total of six projects, that include a promising cancer treatment, a new diagnostic method for Alzheimer’s Disease, an implant helping blindness, lab innovation in biotechnology, and a nutritional intervention for mental health. The researchers will develop a solid business case for their innovations in the time […]
News
Start-up VU-AMS has big plans with clever stress monitoring device
VU-AMS is on a mission to revolutionize how we understand and manage stress-related health issues. Now an official VU spin-off, there are big plans for clinical applications. Founder of VU AMS Martin Gevonden explains: “We offer researchers autonomic biomarkers that are valid, reliable and easy to use, without getting under the skin.” After thriving in […]
News